Due to the large amount of PD-L1 expression in spleen and LNs, the enrichment of αPD-L1 in tumors after intravenous injection was not satisfied, so a generous portion of the free aPD-L1 may bind to normal tissues provokes on-target off-tumor immune-related adverse effects (irAEs) [49]. This evidence concerns the gene CD274 and neoplasm.